Adherence to endocrine therapy in women with breast cancer: development and preliminary validation of the A-BET questionnaire

Clin Ter. 2022 Jul-Aug;173(4):324-333. doi: 10.7417/CT.2022.2441.

Abstract

Purpose: To develop an Italian tool that measures the therapy adherence of women with breast cancer undergoing treatment with oral endocrine therapy.

Methods: A two-phase study was conducted, which followed the guidelines of the European Statistical System for the development and validation of a questionnaire. In the first phase, the questionnaire was developed; in the second phase, a preliminary validation was carried out on patients with breast cancer undergoing treatment with oral hormonal therapies.

Results: In its final version, the questionnaire presents 6 main items which aim to investigate the level of adherence, the degree of awareness of the nature of the drug taken and the reasons that may influence non-adherence. 82 patients were recruited in the validation study, with an average age of 56.4 years, while for the re-test 40 were selected with an average age of 57.3 years. Content validity reported excellent results. Cronbach's alpha of each item showed a strong degree of correlation.

Conclusions: The creation of a tool for measuring adherence to endocrine therapy in breast cancer patients can be a valuable support for healthcare professionals involved in their care. Future studies should be aimed at using A-BET (Adherence - Breast Endocrine Therapy) on larger cohorts of patients in order to verify its validity / reliability more accurately and to be able to generalize the results.

Keywords: a-bet; adherence; breast cancer; endocrine therapy; questionnaire.

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Female
  • Health Personnel
  • Humans
  • Middle Aged
  • Psychometrics / methods
  • Reproducibility of Results
  • Surveys and Questionnaires